CD38 and Miyoshi myopathy: Furthermore, MM patients treated with anti-CD38 mAbs can develop resistance through reduced NK cells and reduced CD38 expression on NK cells, impairing the mechanism of action of these drugs by reducing the functionality of the effector cells44,45.